Skip to content

Study · Systematic review · n = 21,023 · 2026

4 results

Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: A meta-analysis of randomized controlled trials.

Ko D, Kim DH, Tan FXN, Ho GJK, Chandra R, Xuan ZZ, Jun ETK, Tang NSY, Yang HS, Koh JWH, Danpanichkul P, Dalakoti M and 10 more

Show all authors

Syn NL, Wijarnpreecha K, Takahashi H, Zheng MH, Nakajima A, Noureddin M, Muthiah M, Le Roux CW, Siddiqui MS, Ng CH

Cell reports. Medicine1 Mar 2026Cited by 1 (Europe PMC)

PMID41850241 (opens in a new tab)PMCIDPMC13006432 (opens in a new tab)DOI10.1016/j.xcrm.2026.102614 (opens in a new tab)PepBankPUB-41850241
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of 33 randomised trials of semaglutide, 33.4% of participants did not achieve a total body weight reduction of 5% or more.

    In plain wordsIn 33 trials of semaglutide, 33.4% of people did not lose at least 5% of their body weight.

    Peptide
    Semaglutide
    Outcome
    Not applicableParticipants not achieving at least 5% total body weight reduction
    Study

    n = 21,023

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Proportion not achieving ≥5% weight loss
    33.4%
    all participants

    Source sentences

    Summary
    Across included trials of patients with and without type 2 diabetes, 33.4% and 65.1% of participants did not achieve ≥5% or ≥10% total body weight reduction, respectively.
    1 context sentence
    Summary · context
    We present an analysis including 33 randomized controlled trials (RCTs) comprising 21,023 participants.
  2. 02HumanSystematic reviewEfficacy outcome

    In a meta-analysis of 33 randomised trials of semaglutide, 65.1% of participants did not achieve a total body weight reduction of 10% or more.

    In plain wordsIn 33 trials of semaglutide, 65.1% of people did not lose at least 10% of their body weight.

    Peptide
    Semaglutide
    Outcome
    Not applicableParticipants not achieving at least 10% total body weight reduction
    Study

    n = 21,023

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Proportion not achieving ≥10% weight loss
    65.1%
    all participants

    Source sentences

    Summary
    Across included trials of patients with and without type 2 diabetes, 33.4% and 65.1% of participants did not achieve ≥5% or ≥10% total body weight reduction, respectively.
    1 context sentence
    Summary · context
    We present an analysis including 33 randomized controlled trials (RCTs) comprising 21,023 participants.
  3. 03HumanSystematic reviewEfficacy outcome

    In semaglutide trials, up to 79.8% of participants with type 2 diabetes did not achieve 10% weight loss, a higher rate than among participants without diabetes.

    In plain wordsIn semaglutide trials, people with type 2 diabetes more often missed a 10% weight loss than people without diabetes.

    Peptide
    Semaglutide
    Outcome
    IncreaseParticipants with type 2 diabetes not achieving at least 10% weight loss
    Study

    n: not reported in source

    Comparator
    Participants without T2DM
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Proportion not achieving ≥10% weight loss
    ≤ 79.8%
    T2DM

    Source sentences

    Summary
    Stratified analyses demonstrated higher rates of suboptimal outcomes among individuals with type 2 diabetes mellitus (T2DM
    1 context sentence
    Summary · context
    We present an analysis including 33 randomized controlled trials (RCTs) comprising 21,023 participants.
  4. 04HumanSystematic reviewEfficacy outcome

    In semaglutide trials, 30.1% of participants without type 2 diabetes had a suboptimal outcome in the comparison with the diabetes group (threshold of 10% weight loss).

    In plain wordsIn semaglutide trials, 30.1% of people without type 2 diabetes did not reach the weight loss target.

    Peptide
    Semaglutide
    Outcome
    Not applicableParticipants without type 2 diabetes with suboptimal weight loss (comparison group)
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Proportion with suboptimal outcome
    30.1%
    without T2DM

    Source sentences

    Summary
    compared to 30.1% among individuals without T2DM.
    1 context sentence
    Summary · context
    We present an analysis including 33 randomized controlled trials (RCTs) comprising 21,023 participants.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.